CBFB and cancer: In light of these and our observations reported here it will therefore be interesting to test the synergistic potential of glucocorticoids and inhibi tors of RUNX‐CBFβ functions [Illendula et al., 2016] or their key downstream targets in sphingolipid metabolism [Edmonds et al., 2011] in the growing number of cancers where the RUNX genes are implicated as oncogenic drivers [Ito et al., 2015].